Blood cancer, Cancer, Leukemia, Acute myeloid leukemia
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Revumenib (SNDX-5613) w/ venetoclax and azacitidine in Blood cancer, Cancer, Leukemia, Acute myeloid leukemia. The expected timing is based on the latest available company guidance and may change.
BEAT-AML trial. 12/11/23- Initial safety data presented at ASH 2023. 6/14/24 New updated Ph1b data at EHA '24. 8/1/24- Expansion cohort ongoing to establish RP2D. 5/5/25- Frontline trial initiated. 11/03/25:- BEAT AML Ph1 revumenib+venetoclax+azacitidine continues in newly diagnosed older NPM1m/KMT2Ar AML. 02/26/26:- EHA 2025 BEAT AML Ph1 revumenib+venetoclax+azacitidine showed 67% CR, 88% ORR, 100% MRD negativity. 04/30/26:- BEAT AML Ph1 frontline efficacy and safety data expected in H2 2026. 08/04/26:- BEAT AML frontline data expected at H2 2026 medical meetings.
Verification
Confirm timing and program details against the company announcement or filing.